EyeGate Pharma to Present at the 19th Annual Rodman and Renshaw Global Investment Conference
September 05 2017 - 6:30AM
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the
“Company”), a clinical-stage specialty pharmaceutical company
focused on developing and commercializing products using our two
proprietary platform technologies for treating diseases and
disorders of the eye, today announced that it will be featured as a
presenting company at the 19th Annual Rodman & Renshaw Global
Investment Conference, being held on September 10-12, 2017 at The
Lotte New York Palace Hotel in New York, NY.
Details for the presentation are as
follows:
Date: Tuesday, September 12, 2017Time: 10:00 –
10:25 AM EDTRoom: Holmes II
Investors attending the conference who would
like to schedule a one-on-one meeting with EyeGate’s management may
do so by contacting their Rodman & Renshaw representative, or
Lee Roth or Janhavi Mohite at The Ruth Group at
lroth@theruthgroup.com / jmohite@theruthgroup.com.
About EyeGate:EyeGate is a
clinical-stage specialty pharmaceutical company focused on
developing and commercializing products using its two proprietary
platform technologies for treating diseases and disorders of the
eye. EyeGate’s most advanced platform is based on a cross-linked
thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form
of the natural polymer hyaluronic acid (“HA”), which is a gel that
possesses unique physical and chemical properties such as hydrating
and healing when applied to the ocular surface. The ability of
CMHA-S to adhere longer to the ocular surface, resist degradation
and protect the ocular surface makes it well-suited for treating
various ocular surface injuries.
EGP-437, EyeGate’s other product in clinical
trials, incorporates a reformulated topically active
corticosteroid, Dexamethasone Phosphate that is delivered into the
ocular tissues through EyeGate’s proprietary innovative drug
delivery system, the EyeGate II Delivery System. For more
information, please visit www.EyeGatePharma.com.
Forward-looking StatementsSome
of the statements in this press release are “forward-looking” and
are made pursuant to the safe harbor provision of the Private
Securities Litigation Reform Act of 1995. These “forward-looking”
statements include statements relating to, among other things, the
commercialization efforts and other regulatory or marketing
approval efforts pertaining to EyeGate’s products, including
EyeGate’s EGP-437 combination product and those of Jade
Therapeutics, Inc., a wholly owned subsidiary of EyeGate, as well
as the success thereof, with such approvals or success may not be
obtained or achieved on a timely basis or at all. These statements
involve risks and uncertainties that may cause results to differ
materially from the statements set forth in this press release,
plus other risk factors described under the heading “Risk Factors”
contained in our Annual Report on Form 10-K filed with the SEC on
February 23, 2017 or described in our other public filings. Our
results may also be affected by factors of which we are not
currently aware. The forward-looking statements in this press
release speak only as of the date of this press release. EyeGate
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to such statements to reflect any
change in its expectations with regard thereto or any changes in
the events, conditions or circumstances on which any such statement
is based.
Contact:
Lee Roth / Janhavi Mohite
The Ruth Group for EyeGate Pharmaceuticals
646-536-7012 / 7026
lroth@theruthgroup.com / jmohite@theruthgroup.com
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Apr 2023 to Apr 2024